Evidence map›Paper›PMID 38063980›Full record

ArticleCancer causes & control : CCC2024

Screening history and risk of death from prostate cancer: a nested case-control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC).

Kirsi Talala, Stephen Walter, Kimmo Taari, Teuvo L J Tammela, Paula Kujala, Anssi Auvinen

Abstract read
In one paragraph

Article in Cancer causes & control : CCC, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Prostate Cancer Mortality Trend in Montenegro 1990-2018.Iranian journal of public health · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kirsi TalalaFinnish Cancer Registry, Unioninkatu 22, 00130, Helsinki, Finland. kirsi.talala@cancer.fi.ORCID http://orcid.org/0000-0002-9705-9265
Stephen WalterFaculty of Health Sciences, McMaster University, Hamilton, ON, L8S 3L8, Canada.
Kimmo TaariDepartment of Urology, Helsinki University Hospital and University of Helsinki, 00029, Helsinki, Finland.
Teuvo L J TammelaFaculty of Medicine and Health Technology, Tampere University, 33014, Tampere, Finland.
Paula KujalaDepartment of Pathology, Fimlab Laboratories, 33101, Tampere, Finland.
Anssi AuvinenFaculty of Social Sciences/Health Sciences, Tampere University, 33014, Tampere, Finland.

Funding

Academy of Finland 260931Pirkanmaa Hospital District Competitive Research Funding 9V065
6 · The paper itself

Abstract

purposeWe assessed the risk of death from prostate cancer (PCa) in relation to men's screening histories, i.e., screening attendance among men who were offered screening.

methodsMen in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) screening arm were invited to up to three screening rounds with the serum prostate-specific antigen (PSA) test at 4-year intervals during 1996-2007. Case subjects (n = 330) were men who died from PCa. Each case was matched to five controls (n = 1544) among the men who were free of PCa. Screening history was defined as (1) never/ever attended screening prior to the case diagnosis; (2) attended at the first screening round; and (3) recency of screening, calculated as the time from last screening attendance to the date of case diagnosis. The association between screening history and the risk of death from PCa was estimated by odds ratios (OR) with 95% confidence intervals (CI) using conditional logistic regression.

resultsHaving ever attended screening versus never attended was associated with a reduced risk of PCa death (OR 0.60, 95% CI 0.45-0.81) and a similar association was found for those attended (versus not attended) the first screening round (OR 0.67, 95% CI 0.51-0.87). The effect by time since last screen for the risk of PCa death was significantly lower 2-7 years since last screen.

conclusionAmong men invited to screening, subjects who attended any PSA screening during the previous 19 years had a 40% reduction in PCa mortality compared to non-screened men.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsCase-Control StudiesEarly Detection of CancerFinlandHumansMaleMass ScreeningProstate-Specific AntigenCase–control studyMortalityProstate cancerScreening

Identifiers

PMID38063980
PMCPMC10960891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.